Results 81 to 90 of about 52,382 (294)

Myelodysplastic syndromes and overlap syndromes

BLOOD RESEARCH, 2021
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological neoplasms characterized by ineffective hematopoiesis, morphologic dysplasia, and cytopenia. MDS overlap syndromes include various disorders, such as myelodysplastic/myeloproliferative neoplasms and hypoplastic MDS with aplastic anemia characteristics.
openaire   +3 more sources

Calreticulin Type 26 Mutation in Myelofibrosis: A Rare Variant With Diagnostic Challenges

Journal of Clinical Laboratory Analysis, EarlyView.
ABSTRACT Background Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders commonly driven by mutations in JAK2, MPL, or CALR. Because routine CALR assays are largely optimized for the canonical Type 1 and Type 2 exon 9 variants, rare noncanonical mutations may be missed, creating diagnostic challenges.
Teresa Maltese, Giuseppina Raffa, Fabio Stagno, Rossana Leanza, Paola Barone, Alessandro Allegra, Teresa Pollicino   +6 more
wiley   +1 more source

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

Haematologica, 2016
Disease relapse is the most common cause of treatment failure after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes, yet treatment options for such patients remain extremely limited.
Charles Craddock, Myriam Labopin, Marie Robin, Juergen Finke, Patrice Chevallier, Ibrahim Yakoub-Agha, Jean Henri Bourhis, Henrik Sengelov, Didier Blaise, Thomas Luft, Michael Hallek, Nicolaus Kröger, Arnon Nagler, Mohamad Mohty   +13 more
doaj   +1 more source

Measurement of Active Thrombin Bound to Circulating D‐Dimers as a Sensitive Biomarker for Prothrombotic Conditions

Journal of Clinical Laboratory Analysis, EarlyView.
Scheme of preparation of D‐dimers and evaluation of D‐dimer‐bound thrombin activity. Thrombin bound to fibrin participates in ongoing fibrinogen transformation and its inhibition is impeded. Our detection system may aid in identifying patients at risk of recurrent thrombotic events or complications, regardless of the origin of the acute health problem.
Jana Stikarova, Leona Chrastinova, Kristyna Svobodova, Marek Havlicek, Jan Louzil, Eliska Ceznerova, Alzbeta Hlavackova, Ondrej Pastva, Pavla Pecherkova, Ingrid Hrachovinova, Ondrej Kucerka, Roman Kotlin, Petr Soukup, Peter Salaj, Martin Maly, Jiri Suttnar   +15 more
wiley   +1 more source

Familial myelodysplastic syndromes: a review of the literature

Haematologica, 2011
Familial cases of myelodysplastic syndromes are rare, but are immensely valuable for the investigation of the molecular pathogenesis of myelodysplasia in general.
Elena Liew, Carolyn Owen
doaj   +1 more source

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. [PDF]

, 2009
Progress in the management of patients with myelodysplastic syndromes (MDS) has been hampered by the inability to detect cytogenetic abnormalities in 40-60% of cases.
Bueso-Ramos, CE, Estey, EH, Garcia-Manero, G, Gilliland, DG, Heinrichs, S, Issa, J-P, Kantarjian, HM, Kornblau, SM, Kulkarni, RV, Levine, RL, Li, C, Loh, ML, Look, AT, Neuberg, D   +13 more
core   +1 more source

p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia [PDF]

, 2011
Suppression of apoptosis by TP53 mutation contributes to resistance of acute myeloid leukemia (AML) to conventional cytotoxic treatment. Using differentiation to induce irreversible cell cycle exit in AML cells could be a p53-independent treatment ...
Anjali Advani, Edward Copelan, James C. Mulloy, PhD, Jaroslaw Maciejewski, Kevin Link, Kwok-Peng Ng, Matt Kalaycio, Mikkael Sekeres, Quteba Ebrahem, Reda Mahfouz, Ronald Sobecks, Soledad Negrotto, Tomas Radivoyevitch, Xiaorong Gu, Yogen Saunthararajah, Zhenbo Hu   +15 more
core   +2 more sources

Exportin 1 Inhibitor Combined With Venetoclax Induces Apoptosis in Myelodysplastic Syndrome by Mitochondria‐Induced Apoptosis Pathway

Journal of Clinical Laboratory Analysis, EarlyView.
Inhibition of XPO1 is a promising modality in the treatment of MDS, especially when combined with Venetoclax, which activates mitochondria‐mediated apoptosis and could be a potential target for MDS therapy. ABSTRACT Background Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies that pose a serious health threat.
Xiaohan Liu, Lei Huang, Junzhu Wang, Yixuan Guo, Hongli Shen, Xianghong Zhao, Lanzhu Yue, Zhaoyun Liu, Rong Fu   +8 more
wiley   +1 more source

Myelodysplastic syndromes: the pediatric point of view. [PDF]

, 1995
Myelodysplastic syndromes (MDS) are clonal disorders of the multipotent hematopoietic stem cell characterized by ineffective hematopoiesis and associated with marrow hypercellularity, increased intramedullary cell death and peripheral cytopenias of ...
DE STEFANO P., LOCATELLI F., MASERATI, EMANUELA, PESSION A., SEVERI F., ZECCA M.   +5 more
core  

A new method for maturity-dependent fractionation of neutrophil progenitors applicable for the study of myelodysplastic syndromes [PDF]

, 2014
We applied our new method, maturity-dependent fractionation of bone marrow-derived neutrophil progenitors, to a study of gene expression profiles during granulopoiesis in myelodysplastic syndromes.
Hideo Kimura, Hideyoshi Noji, Huiyuan Hu, Junko Kimura, Kazuei Ogawa, Kazuhiko Ikeda, Kazuko Akutsu, Tomoyuki Ono, Tsutomu Shichishima, Yasuchika Takeishi, Yayoi Shikama   +10 more
core   +1 more source